AstraZeneca’s first quarter results (PDF) put a twist on a fairy tale, telling the lesser-known story of GOLDILOX and the porcupine. The drugmaker axed a cardiovascular disease prospect after wrapping up the phase 2 GOLDILOX trial while stopping work on early-stage assets bought in from Ionis and Redx Pharma.
Jazz Pharma and Redx Pharma link up on KRAS inhibitor program
(Reuters) - Jounce Therapeutics Inc on Monday agreed to be acquired by privately held Concentra Biosciences for $96.46 million, while spurning a merger deal with British biotech firm Redx Pharma.
Just last month, Jounce Therapeutics jumped at the chance for a reverse merger into Redx Pharma after conceding its cancer meds were unlikely to advance any further into clinic. Now, the surprise arrival of another offer leaves Jounce in the unexpected position of fighting off prospective suitors.
Redx has hit a thorny patch. In the first data from a phase 2 program, Redx’s porcupine inhibitor RXC004 failed to improve progression-free survival in biliary tract cancer (BTC), prompting the British biotech to stop monotherapy development and focus on combinations in the indication.
(Reuters) -British biotech firm Redx Pharma plc and U.S.-based Jounce Therapeutics Inc will merge to create a $425 million entity specialised in treating cancer and fibrotic disease.
Redx Pharma plans to conduct a Phase IIb study further investigating RXC007 in idiopathic pulmonary fibrosis (IPF), says Dr Jane Robertson, CMO at Redx. The trial is expected to start in mid-2024, after the completion and data readout of the ongoing Phase IIa study in H2 2023.
Ireland-based Jazz Pharmaceuticals and Redx have announced that the US Food and Drug Administration (FDA) has cleared an application for JZP815.
Redx Pharma, the Macclesfield-based drugs discovery company focused on the treatment of cancer and fibrotic disease, has received a $5m milestone payment after one of its products was cleared for clinical development.
Alderley Park, 5 February 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncologyand fibrosis, today announces that its Annual General Meeting will be held at 11am on 2 March 2021 at Block 33, Mereside,Alderley Park, Macclesfield SK10 4TG.